Pfizer, Flynn Pharma, UK watchdog granted appeals in long-running pricing case
By Simon Zekaria ( June 19, 2026, 14:08 GMT | Insight) -- Pfizer, Flynn Pharma and the UK's Competition and Markets Authority have won appeals against a court ruling in the latest chapter in their long-running epilepsy drug pricing case. The companies were originally sanctioned by the competition watchdog in 2016 over the price of phenytoin sodium capsules, triggering a legal battle which has led to revised penalties and raised questions about the CMA's handling of the case.Drugmakers Pfizer and Flynn Pharma and the UK's Competition and Markets Authority have won appeals against a competition court ruling in the latest chapter in their long-running epilepsy drug pricing case....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.